Drug Profile
Tisotumab vedotin - Genmab/Seagen
Alternative Names: HuMax-TF; HuMax-TF-ADC; Humax®-TF-ADC; TF-011-MMAE; Tisotumab vedotin-tftv - Genmab/Seagen; TIVDAKLatest Information Update: 07 Feb 2024
Price :
$50
*
At a glance
- Originator Genmab
- Developer Genmab; Seagen; ZAI Lab
- Class Antineoplastics; Auristatins; Drug conjugates; Immunotherapies; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cervical cancer
- Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
Most Recent Events
- 02 Feb 2024 Preregistration for Cervical cancer (Metastatic disease, Second-line therapy or greater, Recurrent) in European Union (IV)
- 09 Jan 2024 FDA assigns PDUFA action date of (09/05/2024) for tisotumab vedotin (full approval) for Cervical cancer
- 09 Jan 2024 The US FDA accepts sBLA seeking to convert the accelerated approval to full approval for tisotumab vedotin for Cevical cancer (Metastatic disease, Second-line therapy or greater) for review